Leidi.com Lei Jianping September 14
Yantai McBerry International Biopharmaceutical Co., Ltd. (referred to as "Mabray") recently passed its IPO and is preparing to be listed on the GEM of the Shenzhen Stock Exchange.
McBerry plans to raise 1.6 billion yuan, of which 1.12 billion yuan will be used for the construction project of the biomedical innovation center and operation headquarters, and 480 million yuan will be used for supplementary working capital projects.
Annual revenue 500 million
Founded in 2013, McBerry is a CDMO company focusing on the field of biopharmaceuticals. It focuses on providing professional services for biopharmaceuticals such as monoclonal antibodies, double antibodies, polyclonal antibodies, fusion proteins, antibody-conjugated drugs, recombinant vaccines, and recombinant proteins. , customized and integrated CDMO services.
McBerry covers the entire chain from early R&D, cell line development, production process development, analytical method development, quality research, clinical sample production, domestic and foreign IND/BLA filing to large-scale commercial production.
The prospectus shows that McBerry's revenue in 2020, 2021, and 2022 will be 217 million yuan, 388 million yuan, and 508 million yuan respectively; net profits will be -4.0386 million yuan, 60.5267 million yuan, and 132 million yuan respectively; after deducting non-profit Net profits were -21.0487 million yuan, 28.11 million yuan, and 95.43 million yuan respectively.
Wang Weidong and Fang Jianmin control 33% of the voting rights
Wang Weidong, Fang Jianmin, Lin Jian, Wang Liqiang, Wang Xudong, Deng Yong, Xiong Xiaobin, Wen Qingkai, Yang Minhua and Wei Jianliang, a total of 10 natural persons, are the joint actual controllers of the company. Wang Weidong and Wang Xudong are brothers, and Deng Yong is the spouse of Wang Weidong and Wang Xudong's sister Wang Xiuping.
As of the signing date of this prospectus, the aforementioned joint actual controllers control a total of 32.95% of the company through direct shareholdings and Yantai Rongchang Partnership, Yantai Zengrui, Mabplex Holding, Yantai Hengrong, Yantai Jianshun, Yantai Yirui, Yantai Yida and Yantai Jichang. The company's shareholding structure is relatively dispersed.
The above-mentioned joint actual controllers and relevant entities signed a concerted action agreement in March 2022, committing to make decisions on major matters of the company within at least 36 months from the date of signing of the concerted action agreement to the date when the company’s shares are listed on A-shares. Concerted actions will be taken to ensure the stability of company control.
Before the IPO, Yantai Yeda (SS) held 18.92% of the shares, Yantai Rongchang Partnership held 10.53%, SDIC Venture Fund held 8.34%, Yantai Zengrui held 6.31%, and Fang Jianmin held 6.23%. %, Mabplex Holding holds 2.94%, Tongji Innovation (SS) holds 2.84%, Yantai Xinzhen and Sunshine Life Insurance hold 2.57% respectively;
Huachen Finance holds 2.45%, Shandong Jifu holds 2.15%, Shenzhen Venture Capital (CS) holds 2.12%, PAG HoldingI holds 2%, Yantai Hengrong holds 1.98%, Worldwide Healthcare, Detong Hexin and Zhuhai Huajin each hold 1.61% of the shares, Yantai Jianshun holds 1.6%, Beijing Wuyoun holds 1.45%, and Shenzhen Hongtu holds 1.35%.
Yantai Zhaorui and Yantai Yirui hold 1.26% of the shares respectively, Yantai Yida holds 1.23% of the shares, Gao Investment Mingli holds 1.09% of the shares, Lutai Textile holds 1.02% of the shares, Yantai Innovation holds 0.97% of the shares, and Yantai Innovation holds 0.97% of the shares. Jichang holds 0.88% of the shares, Yantai Financial (SS) holds 0.84%, Qingdao Yuanchuang and Huachen Jishi hold 0.8% respectively, Tongsheng Biotech holds 0.76%, Beijing Longpan and SDIC Venture Together they hold 0.71% of the shares, Qingdao Zhongtai holds 0.69%, Qingdao Hengshuo, Duoying New Energy, and China Merchants Investment (SS) hold 0.64% respectively, Yantai Venture Capital holds 0.49%, Taifu Investment, Shanghai Chongyuan holds 0.42% of the shares respectively.
Fang Jianmin, born in May 1962, male, Canadian nationality, Ph.D. Obtained a PhD in biology from Dalhousie University in Canada in December 1997. From 2000 to 2008, he engaged in postdoctoral research in cancer at Harvard Medical School and Boston Children's Hospital. Served as a director of Rongchang Biotech from October 2008 to April 2020; served as CEO and chief scientific officer of Rongchang Biotech from October 2008 to present;
Fang Jianmin has served as the director of Rongchang Biotech USA from April 2011 to the present; as the general manager of McBerry from June 2013 to March 2020; as the chairman of McBary from June 2013 to the present; and as Rongchang Pharmaceutical from January 2017 to the present. Director; from September 2017 to June 2020, he served as the director of Yeda Incubation; from September 2019 to the present, he served as the director of Rongchang Biotech Hong Kong; from May 2020 to the present, he served as the executive director of Rongchang Biotech; from May 2020 to the present, he served as the executive director of Rongchang Biotech Shanghai .
Wang Weidong, born in September 1959, received a bachelor's degree in traditional Chinese medicine and pharmacy from Heilongjiang Business College (now Harbin University of Commerce) in July 1982. Founded Rongchang Pharmaceutical in March 1993 and serves as the chairman until now; has served as the issuer’s director since June 2013; has served as the director of Rongchang Biotech from October 2013 to April 2020; has served as the director of Rongchang Biotech USA from January 2015 to the present;
Wang Weidong served as the director of Medberry USA from November 2015 to June 2020; as the director of Saipu Biotech from June 2018 to April 2020; as the chairman of Rongchang Biotech from June 2019 to the present; as the chairman of Rongchang Biotech from May 2020 to the present Executive Director of Biology; from October 2020 to December 2021, he served as chairman of Yantai Rongrui.
Prior to this, Rongchang Biology, a company jointly created by Wang Weidong and Fang Jianmin, had been listed on the Hong Kong stock market and the Science and Technology Innovation Board.
After the IPO, Yantai Yeda (SS) held 15.13% of the shares, Yantai Rongchang Partnership held 8.42%, SDIC Venture Fund held 6.67%, Yantai Zengrui held 5.04%, and Fang Jianmin held 4.98%. %, Mabplex Holding holds 2.35%, Tongji Innovation (SS) holds 2.27%, Yantai Xinzhen and Sunshine Life hold 2.06% respectively;
Huachen Finance holds 1.96%, Shandong Jifu holds 1.72%, Shenzhen Venture Capital (CS) holds 1.7%, PAG HoldingI holds 1.6%, Yantai Hengrong holds 1.58%, Worldwide Healthcare, Detonghe Xinxin and Zhuhai Huajin each hold 1.29% of the shares, Yantai Jianshun holds 1.28%, Beijing Wuyoun holds 1.16%, and Shenzhen Hongtu holds 1.08%.
Yantai Zhaorui and Yantai Yirui hold 1.01% of the shares respectively, Yantai Yida holds 0.98% of the shares, Gao Investment Mingli holds 0.88% of the shares, Lutai Textile holds 0.82% of the shares, Yantai Innovation holds 0.77%, and Yantai Innovation holds 0.77% of the shares. Jichang holds 0.7% of the shares, Yantai Finance (SS) holds 0.67% of the shares, Qingdao Yuanchuang and Huachen Jishi hold 0.64% of the shares respectively, and Tongsheng Biotech holds 0.61%;
Beijing Longpan and SDIC Chuanghe hold 0.57% of the shares respectively, Qingdao Zhongtai holds 0.55% of the shares, Qingdao Hengshuo, Duoying New Kinetics, and China Merchants Investment (SS) hold 0.51% of the shares respectively, and Yantai Venture Capital holds 0.51% of the shares. 0.39%, with Taifu Investment and Shanghai Chongyuan holding 0.34% respectively.
———————————————
Leidi was founded by media person Lei Jianping. If you reprint, please indicate the source.
